Skip to main content

CORRECTION article

Front. Oncol.
Sec. Pharmacology of Anti-Cancer Drugs
Volume 14 - 2024 | doi: 10.3389/fonc.2024.1532291

Corrigendum: CDK4/6 inhibitors improve the anti-tumor efficacy of Lenvatinib in hepatocarcinoma cells.

Provisionally accepted
Graziana Digiacomo Graziana Digiacomo 1Claudia Fumarola Claudia Fumarola 1Silvia La Monica Silvia La Monica 1*Mara Bonelli Mara Bonelli 1Andrea Cavazzoni Andrea Cavazzoni 1*Maricla Galetti Maricla Galetti 2Rita Terenzani Rita Terenzani 1Kamal Eltayeb Kamal Eltayeb 1Francesco Volta Francesco Volta 1Silvia Zoppi Silvia Zoppi 1Patrizia Bertolini Patrizia Bertolini 3Gabriele Missale Gabriele Missale 1,4Roberta Alfieri Roberta Alfieri 1Pier Giorgio Petronini Pier Giorgio Petronini 1
  • 1 Department of Medicine and Surgery, University of Parma, Parma, Italy
  • 2 Department of Occupational and Environmental Medicine, Epidemiology and Hygiene, INAIL - Italian Workers’ Compensation Authority, Rome, Italy
  • 3 Paediatric Hematology Oncology Unit, University Hospital of Parma, Parma, Italy
  • 4 Unit of Infectious Diseases and Hepatology, University Hospital of Parma, Parma, Italy

This article is a correction to:

  1. CDK4/6 inhibitors improve the anti-tumor efficacy of lenvatinib in hepatocarcinoma cells

    1. Read original article

The final, formatted version of the article will be published soon.

    • please read through all the templates before choosing • pick the most relevant text template(s) from the following page and delete all others.• edit the text as necessary, ensuring that the original incorrect text is included for the record, please see the below. • please do not use any extra formatting when editing the templates, and only modify the red text unless absolutely necessary • submit to Frontiers following the instructions on this page.When the original text contained incorrect information, to preserve the scientific record, please include that text when editing the below templates. For example:There was a mistake in the Funding statement, an incorrect number was used. The correct number is "2015C03Bd051.". The publisher apologizes for this mistake.The original version of this article has been updated.

    Keywords: Hepatocarcinoma (HCC), CDK4/6 inhibition, Abemaciclib, Lenvatinib, senescence

    Received: 21 Nov 2024; Accepted: 26 Nov 2024.

    Copyright: © 2024 Digiacomo, Fumarola, La Monica, Bonelli, Cavazzoni, Galetti, Terenzani, Eltayeb, Volta, Zoppi, Bertolini, Missale, Alfieri and Petronini. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Silvia La Monica, Department of Medicine and Surgery, University of Parma, Parma, Italy
    Andrea Cavazzoni, Department of Medicine and Surgery, University of Parma, Parma, Italy

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.